Phosphate binders for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis: A comparison of safety profiles

Expert Opinion on Drug Safety

Volumn 13, Issue 5, 2014, Pages 551-561

  Locatelli, Francesco ^a   Del Vecchio, Lucia ^a   Violo, Leano ^a   Pontoriero, Giuseppe ^a  

^a A MANZONI HOSPITAL   (Italy)

Author keywords

Chronic kidney disease; Dialysis; Hyperphosphatemia; Low density lipoprotein cholesterol; Non calcium phosphate binders; Phosphate binder; Safety; Tolerability

Indexed keywords

ALPHA TOCOPHEROL; ALUMINUM; ALUMINUM HYDROXIDE; ALUMINUM SALT; BILE ACID SEQUESTRANT; CALCIUM ACETATE; CALCIUM ACETATE PLUS MAGNESIUM CARBONATE; CALCIUM CARBONATE; CIPROFLOXACIN; COLESTILAN; CYCLOSPORIN; DIGOXIN; LANTHANUM; LANTHANUM CARBONATE; MAGNESIUM CARBONATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PHOSPHATE BINDING AGENT; PHOSPHORUS; PLACEBO; RETINOL; SEVELAMER; SEVELAMER CARBONATE; TETRACYCLINE DERIVATIVE; UNCLASSIFIED DRUG; VITAMIN D; VITAMIN K GROUP; PHOSPHATE;

ABDOMINAL PAIN; ANEMIA; AORTA CALCIFICATION; AORTA DISEASE; BLOOD VESSEL CALCIFICATION; BRAIN DISEASE; CALCIUM BALANCE; CHRONIC KIDNEY DISEASE; COGNITIVE DEFECT; CONSTIPATION; CORONARY ARTERY CALCIFICATION; CORONARY ARTERY CALCIUM SCORE; DEMENTIA; DIARRHEA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG SAFETY; DRUG TISSUE LEVEL; DRUG TOLERABILITY; DYSPEPSIA; GASTRITIS; GASTROINTESTINAL ABSORPTION; GASTROINTESTINAL SYMPTOM; HEMODIALYSIS PATIENT; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; INTESTINE OBSTRUCTION; INTESTINE PERFORATION; ION EXCHANGE; META ANALYSIS (TOPIC); MICROCYTIC ANEMIA; NAUSEA; OSTEOMALACIA; PHOSPHATE BALANCE; PHOSPHATE BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL REPLACEMENT THERAPY; REVIEW; RISK FACTOR; VOMITING; ANTAGONISTS AND INHIBITORS; COMPLICATION; METABOLISM; RENAL INSUFFICIENCY, CHRONIC;

HUMANS; HYPERPHOSPHATEMIA; PHOSPHATES; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84899125477     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2014.907791     Document Type: Review

References (96)

1. Hutchison AJ, Smith CP, Brenchley PEC. Pharmacology, efficacy and safety of oral phosphate binders. Nat Rev Nephrol 2011;7:578-89
2. Phosphate binder use (national sample). US DOPPS Practice Monitor, October. 2013. Available from: www.dopps.org/DPM [Last accessed 5 November 2013]
3. Martin KJ, Gonzalez EA. Metabolic bone disease in chronic kidney disease. J Am Soc Nephrol 2007;18(3):875-85
4. Mathew S, Tustison KS, Sugatani T, et al. The mechanism of phosphorus as a cardiovascular risk factor in CKD. J Am Soc Nephrol 2008;19(6):1092-105
5. Slinin Y, Foley RN, Collins AJ. Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study. J Am Soc Nephrol 2005;16(6):1788-93
6. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998;31(4):607-17
7. Young EW, Albert JM, Satayathum S, et al. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2005;67(3):1179-87
8. Melamed ML, Eustace JA, Plantinga L, et al. Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study. Kidney Int 2006;70(2):351-7
9. Isakova T, Gutierrez OM, Chang Y, et al. Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol 2009;20(2):388-96
10. Lopes AA, Tong L, Thumma J, et al. Phosphate binder use and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS): evaluation of possible confounding by nutritional status. Am J Kidney Dis 2012;60(1):90-101
11. Cannata-And?a JB, Fernandez-Mart?n JL, Locatelli F, et al. Use of phosphatebinding agents is associated with a lower risk of mortality. Kidney Int 2013;84(5):998-1008.
12. Winkelmayer WC, Liu J, Kestenbaum B. Comparative effectiveness of calciumcontaining phosphate binders in incident U.S. dialysis patients. Clin J Am Soc Nephrol 2011;6(1):175-83
13. Jamal SA, Vandermeer B, Raggi P, et al. Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. Lancet 2013;382(9900):1268-77
14. Di Iorio B, Bellasi A, Russo D, INDEPENDENT Study Investigators. Mortality in kidney disease patients treated with phosphate binders: a randomized study. Clin J Am Soc Nephrol 2012;7(3):487-93
15. Suki WN, Zabaneh R, Cangiano JL, et al. Effects of sevelamer and calciumbased phosphate binders on mortality in hemodialysis patients. Kidney Int 2007;72(9):1130-7
16. Giachelli CM. The emerging role of phosphate in vascular calcification. Kidney Int 2009;75(9):890-7
17. Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000;342(20):1478-83
18. Raggi P, Boulay A, Chasan-Taber S, et al. Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 2002;39(4):695-701
19. Guerin AP, London GM, Marchais SJ, Metivier F. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 2000;15(7):1014-21
20. Block GA, Raggi P, Bellasi A, et al. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007;71(5):438-41
21. London GM, Guerin AP, Marchais SJ, et al. Arterial media calcification in endstage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003;18(9):1731-40
22. Verbeke F, Van Biesen W, Honkanen E, et al.; CORD Study Investigators. Prognostic value of aortic stiffness and calcification for cardiovascular events and mortality in dialysis patients: outcome of the calcification outcome in renal disease (CORD) study. Clin J Am Soc Nephrol 2011;6(1):153-9
23. Moe SM, Chertow GM. The case against calcium-based phosphate binders. Clin J Am Soc Nephrol 2006;1(4):697-703
24. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009;9(Suppl 3):S1-155
25. Kalantar-Zadeh K, Gutekunst L, Mehrotra R, et al. Understanding sources of dietary phosphorus in the treatment of patients with chronic kidney disease. Clin J Am Soc Nephrol 2010;5(3):519-30
26. Pohlmeier R, Vienken J. Phosphate removal and hemodialysis conditions. Kidney Int Suppl 2001;78:S190-4
27. Summary of product characteristics: renvela 800 mg film coated tablets. Sanofi. 2011. Available from: www.medicines.org/emc [Last accessed 9 November 2013]
28. Summary of product characteristics: Fosrenol 500 mg, 750 mg & 1000 mg chewable tablets. Shire. 2013. Available from: www.medicines. org/emc [Last accessed 9 November 2013]
29. Savory J, Bertholf RL, Wills MR. Aluminium toxicity in chronic renal insufficiency. Clin Endocrinol Metab 1985;14(3):681-702
30. Janssen MJ, van der Kuy A, ter Wee PM, van Boven WP. Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients. Clin Nephrol 1996;45(2):111-19
31. Mudge DW, Johnson DW, Hawley CM, et al. Do aluminium-based phosphate binders continue to have a role in contemporary nephrology practice? BMC Nephrol 2011;12:20
32. Tonelli M, Pannu N, Manns B. Oral phosphate binders in patients with kidney failure. N Engl J Med 2010;362(14):1312-24
33. Tzanakis IP, Papadaki AN, Wei M, et al. Magnesium carbonate for phosphate control in patients on hemodialysis. A randomized controlled trial. Int Urol Nephrol 2008;40(1):193-201
34. de Francisco AL, Leidig M, Covic AC, et al. Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability. Nephrol Dial Transplant 2010;25(11):3707-17
35. Summary of product characteristics: osvaren 435 mg/235 mg film-coated tablets. Fresnius Medical Care. 2011. Available from: www.medicines. org/emc [Last accessed 9 November 2013]
36. Navaneethan SD, Palmer SC, Vecchio M, et al. Phosphate binders for preventing and treating bone disease in chronic kidney disease patients. Cochrane Database Syst Rev 2011;(2):CD006023
37. Bellinghieri G, Santoro D, Savica V. Emerging drugs for hyperphosphatemia. Expert Opin Emerg Drugs 2007;12(3):355-65
38. Ben Hamida F, el Esper I, Compagnon M, et al. Long-term (6 months) cross-over comparison of calcium acetate with calcium carbonate as phosphate binder. Nephron 1993;63(3):258-62
39. Autissier V, Damment SJ, Henderson RA. Relative in vitro efficacy of the phosphate binders lanthanum carbonate and sevelamer hydrochloride. J Pharm Sci 2007;96(10):2818-27
40. Damment SJ, Pennick M. Clinical pharmacokinetics of the phosphate binder lanthanum carbonate. Clin Pharmacokinet 2008;47(9):553-63
41. Wilson R, Zhang P, Smyth M, Pratt R. Assessment of survival in a 2-year comparative study of lanthanum carbonate versus standard therapy. Curr Med Res Opin 2009;25(12):3021-8
42. Burke SK, Slatopolsky EA, Goldberg DI. RenaGel, a novel calcium- and aluminium-free phosphate binder, inhibits phosphate absorption in normal volunteers. Nephrol Dial Transplant 1997;12(8):1640-4
43. Delmez J, Block G, Robertson J, et al. A randomized, double-blind, crossover design study of sevelamer hydrochloride and sevelamer carbonate in patients on hemodialysis. Clin Nephrol 2007;68(6):386-91
44. Evenepoel P, Selgas R, Caputo F, et al. Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis. Nephrol Dial Transplant 2009;24(1):278-85
45. Borzecki AM, Lee A, Wang SW, et al. Survival in end stage renal disease: calcium carbonate vs. sevelamer. J Clin Pharm Ther 2007;32(6):617-24
46. Di Iorio B, Molony D, Bell C, et al.; INDEPENDENT Study Investigators. Sevelamer versus calcium carbonate in incident hemodialysis patients: results of an open-label 24-month randomized clinical trial. Am J Kidney Dis 2013;62(4):771-8
47. Ketteler M, Wuthrich RP, Floege J. Management of hyperphosphataemia in chronic kidney disease - challenges and solutions. Clin Kidney J 2013;6:128-36
48. 2012 Annual report of the Dialysis Outcomes and Practice Patterns Study: haemodialysis data 1997-2011. Arbor Research Collaborative for Health, Ann Arbor, Michigan, USA. Available from: www.dopps.org [Last accessed 1 December 2013]
49. Bushinsky DA. Contribution of intestine, bone, kidney, and dialysis to extracellular fluid calcium content. Clin J Am Soc Nephrol 2010;5(Suppl 1):S12-22
50. Bellasi A, Galassi A, Papagni S, Cozzolino M. Cardiac valve calcification: an immutable pathologic finding in chronic kidney disease? J Nephrol 2013;26(4):606-9
51. Hill K, Martin B, Wastney M, et al. Oral calcium carbonate affects calcium but not phosphorus balance in stage 3-4 chronic kidney disease. Kidney Int 2013;83:959-66
52. Tonelli M, Wiebe N, Culleton B, et al.; Alberta Kidney Disease Network. Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients. Nephrol Dial Transplant 2007;22(10):2856-66
53. Locatelli F, Spasovski G, Dimkovic N, et al. The effects of colestilan versus placebo and sevelamer in patients with CKD 5D and hyperphosphataemia: a 1-year prospective randomized study. Nephrol Dial Transplant 2013; published online 2 December 2013, doi:10.1093/ndt/gft476.
54. Zhang C, Wen J, Li Z, Fan J. Efficacy and safety of lanthanum carbonate on chronic kidney disease - mineral and bone disorder in dialysis patients: a systematic review. BMC Nephrol 2013;14(1):226
55. Chertow GM, Burke SK, Raggi P; Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002;62(1):245-52
56. Block GA, Spiegel DM, Ehrlich J, et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2005;68(4):1815-24
57. Asmus HG, Braun J, Krause R, et al. Two year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density. Nephrol Dial Transplant 2005;20(8):1653-61
58. Qunibi W, Moustafa M, Muenz LR, et al.; CARE-2 Investigators. A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation- 2 (CARE-2) study. Am J Kidney Dis 2008;51(6):952-65
59. Barreto DV, Barreto Fde C, de Carvalho AB, et al. Phosphate binder impact on bone remodeling and coronary calcification - results from the BRiC study. Nephron Clin Pract 2008;110(4):c273-83
60. Toussaint ND, Lau KK, Polkinghorne KR, Kerr PG. Attenuation of aortic calcification with lanthanum carbonate versus calcium-based phosphate binders in haemodialysis: a pilot randomized controlled trial. Nephrology (Carlton) 2011;16(3):290-8
61. Ohtake T, Kobayashi S, Oka M, et al. Lanthanum carbonate delays progression of coronary artery calcification compared with calcium-based phosphate binders in patients on hemodialysis: a pilot study. J Cardiovasc Pharmacol Ther 2013;18(5):439-46
62. Spiegel DM, Farmer B. Long-term effects of magnesium carbonate on coronary artery calcification and bone mineral density in hemodialysis patients: a pilot study. Hemodial Int 2009;13(4):453-9
63. Madan P, Bhayana S, Chandra P, Hughes JI. Lower gastrointestinal bleeding: association with sevelamer use. World J Gastroenterol 2008;14(16):2615-16
64. Summary of product characteristics: renagel 800 mg film-coated tablets. Sanofi. 2011. Available from: www.medicines.org/emc [Last accessed 9 November 2013]
65. Grinfeld J, Inaba A, Hutchison AJ. Update and critical appraisal of sevelamer in the management of chronic renal failure. Open Access J Urol 2010;2:161-70
66. Abraham G, Kher V, Saxena S, et al. Sevelamer carbonate experience in Indian end stage renal disease patients. Indian J Nephrol 2012;22(3):189-92
67. Hertel JE, Nakajima S, Sano H, et al. Colestilan (MCI-196), a new calciumfree phospjate binder, is safe and effective in stage 5 CKD dialysis patients: phase 3, randomized, double-blind (DB), placebo (PBO)-controlled, multicenter study [abstract F-PO1862]. J Am Soc Nephrol 2010;21:538A
68. Locatelli F, Dimkovic N, Spasovski G. Evaluation of colestilan in chronic kidney disease dialysis patients with hyperphosphataemia and dyslipidaemia: a randomized, placebo-controlled, multiple fixed-dose trial. Nephrol Dial Transplant 2013;28(7):1874-88
69. European Medicines Agency. Bindren 92 - Public assessment report. 2012. Available from: www.ema.europa. eu/ema/index.jsp?curl=pages/medicines/human/ medicines/002377/human-med-001595. jsp&mid=WC0b01ac058001d124 [Last accessed 9 November 2013]
70. Summary of product characteristics: bindRen 1 g film-coated tablets. Mitsubish. 2013. Available from: www.medicines. org/emc [Last accessed 9 November 2013]
71. Alfrey AC, LeGendre GR, Kaehny WD. The dialysis encephalopathy syndrome. Possible aluminum intoxication. N Engl J Med 1976;294(4):184-8
72. Malluche HH. Aluminium and bone disease in chronic renal failure. Nephrol Dial Transplant 2002;17(Suppl 2):21-4
73. Navarro-Gonzalez JF, Mora-Fernandez C, Garc?a-Perez J. Clinical implications of disordered magnesium homeostasis in chronic renal failure and dialysis. Semin Dial 2009;22(1):37-44
74. Contiguglia SR, Alfrey AC, Miller N, Butkus D. Total-body magnesium excess in chronic renal failure. Lancet 1972;1(7764):1300-2
75. Covic A, Passlick-Deetjen J, Kroczak M, et al. A comparison of calcium acetate/magnesium carbonate and sevelamerhydrochloride effects on fibroblast growth factor-23 and bone markers: post hoc evaluation from a controlled, randomized study. Nephrol Dial Transplant 2013;28(9):2383-92
76. Damment SJ, Pennick M. Clinical pharmacokinetics of the phosphate binder lanthanum carbonate. Clin Pharmacokinet 2008;47(9):553-63
77. Spasovski GB, Sikole A, Gelev S, et al. Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up. Nephrol Dial Transplant 2006;21(8):2217-24
78. Bronner F, Slepchenko BM, Pennick M, Damment SJ. A model of the kinetics of lanthanum in human bone, using data collected during the clinical development of the phosphate binder lanthanum carbonate. Clin Pharmacokinet 2008;47(8):543-52
79. Malluche HH, Siami GA, Swanepoel C, et al.; SPD405-307 Lanthanum Carbonate Study Group. Improvements in renal osteodystrophy in patients treated with lanthanum carbonate for two years. Clin Nephrol 2008;70(4):284-95
80. Hutchison AJ, Barnett ME, Krause R, et al.; SPD405-309 Lanthanum Study Group. Long-term efficacy and safety profile of lanthanum carbonate: results for up to 6 years of treatment. Nephron Clin Pract 2008;110(1):c15-23
81. Altmann P, Barnett ME, Finn WF, SPD405-307 Lanthanum Carbonate Study Group. Cognitive function in Stage 5 chronic kidney disease patients on hemodialysis: no adverse effects of lanthanum carbonate compared with standard phosphate-binder therapy. Kidney Int 2007;71(3):252-9
82. Zamfirescu I, Carlson HE. Absorption of levothyroxine when coadministered with various calcium formulations. Thyroid 2011;21(5):483-6
83. Liel Y, Sperber AD, Shany S. Nonspecific intestinal adsorption of levothyroxine by aluminum hydroxide. Am J Med 1994;97(4):363-5
84. Arnadottir M, Johannesson AJ. Phosphate binders and timing of levothyroxine administration. Nephrol Dial Transplant 2008;23(1):420
85. Weitzman SP, Ginsburg KC, Carlson HE. Colesevelam hydrochloride and lanthanum carbonate interfere with the absorption of levothyroxine. Thyroid 2009;19(1):77-9
86. Kays MB, Overholser BR, Mueller BA, et al. Effects of sevelamer hydrochloride and calcium acetate on the oral bioavailability of ciprofloxacin. Am J Kidney Dis 2003;42(6):1253-9
87. How PP, Fischer JH, Arruda JA, Lau AH. Effects of lanthanum carbonate on the absorption and oral bioavailability of ciprofloxacin. Clin J Am Soc Nephrol 2007;2(6):1235-40
88. Summary of product characteristics: calcichew 500 mg chewable tablets. Shire. 2010. Available from: www.medicines. org/emc [Last accessed 9 November 2013]
89. Summary of product characteristics: alu-cap capsules. Meda. 2013. Available from: www.medicines.org/emc [Last accessed 9 November 2013]
90. Brown DD, Juhl RP. Decreased bioavailability of digoxin due to antacids and kaolin-pectin. N Engl J Med 1976;295(19):1034-7
91. Burke S, Amin N, Incerti C, et al. Sevelamer hydrochloride (Renagel), a nonabsorbed phosphate-binding polymer, does not interfere with digoxin or warfarin pharmacokinetics. J Clin Pharmacol 2001;41(2):193-8
92. Vella A, Gerber TC, Hayes DL, Reeder GS. Digoxin, hypercalcaemia, and cardiac conduction. Postgrad Med J 1999;75(887):554-6
93. Summary of product characteristics: phosex 1000 mg tablets. Pharmacosmos. 2011. Available from: www.medicines. org/emc [Last accessed 9 November 2013]
94. Pieper AK, Buhle F, Bauer S, et al. The effect of sevelamer on the pharmacokinetics of cyclosporin A and mycophenolate mofetil after renal transplantation. Nephrol Dial Transplant 2004;19(10):2630-3
95. Cozzlino M, Rizzo MA, Stucchi A, et al. Sevelamer for hyperphosphataemia in kidney failure: controversy and perspective. Ther Adv Chronic Dis 2012;3(2):59-68
96. Locatelli F, Del Vecchio L. Optimal phosphate control: still an unmet need in chronic kidney disease patients. Expert Opin Pharmacother 2014;15(3):307-9